Fortress Biotech (CNB1) Stock Statistics & Valuation Metrics

Fortress Biotech has a market cap or net worth of €45.40M. The enterprise value is €50.83M.

Fortress Biotech has 29,569,553 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fortress Biotech’s return on equity (ROE) is -2.69 and return on invested capital (ROIC) is -155.12%.

The current PE Ratio of Fortress Biotech is -0.40. Fortress Biotech’s PEG ratio is <0.01.

In the last 12 months, Fortress Biotech had revenue of 84.51M and earned -60.64M in profits. Earnings per share was -8.47.

In the last 12 months, operating cash flow was -102.22M and capital expenditures -63.00K, giving a free cash flow of -102.28M billion.

Fortress Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Fortress Biotech upcoming earnings date is May 7, 2025, TBA Not Confirmed.

Fortress Biotech as a current ratio of 1.38, with Debt / Equity ratio of 338.07%

In the past 12 months, Fortress Biotech has paid 521.00K in taxes.

Fortress Biotech EV to EBITDA ratio is -0.24, with an EV/FCF ratio of -0.24.

Fortress Biotech has €58.85M in cash and marketable securities with ― in debt, giving a net cash position of €12.68M billion.

Gross margin is 59.95%, with operating margin of -168.43%, and net profit margin of -71.75%.

The average price target for Fortress Biotech is €14.12, which is 11.43% higher than the current price. The consensus rating is Moderate Buy